Stockreport

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise [Seeking Alpha]

Alumis Inc.  (ALMS) 
PDF Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $ [Read more]